PharmaShots | Incisive News in 3 Shots

Subscribe Now

Celltrion

Celltrion Launches Yuflyma (biosimilar, adalimumab) in the US

Celltrion Launches Yuflyma (biosimilar, adalimumab) in the US

July 4, 2023

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives the US FDA’s Approval for Multiple Indications

Celltrion’s Yuflyma (biosimilar, adalimumab) Receives the US FDA’s Approval for Multiple Indications

May 25, 2023

Celltrion Launches Vegzelma (biosimilar, bevacizumab) for Multiple Cancers in the US

Celltrion Launches Vegzelma (biosimilar, bevacizumab) for Multiple Cancers in the US

April 17, 2023

Celltrion Reports 24 Week P-III Trial Results of CT-P42 (biosimilar, aflibercept) for Wet Age-Related Macular Degeneration and Diabetic Macular Edema

Celltrion Reports 24 Week P-III Trial Results of CT-P42 (biosimilar, aflibercept) for Wet Age-Related Macular Degeneration and Dia...

April 3, 2023

Celltrion Reports P-III Trial Results of CT-P16 (biosimilar, bevacizumab) for Non-Squamous Non–Small Cell Lung Cancer

Celltrion Reports P-III Trial Results of CT-P16 (biosimilar, bevacizumab) for Non-Squamous Non–Small Cell Lung Cancer

January 21, 2023

Celltrion Collaborated with Rani Therapeutics for the Development of RT-111 (biosimilar, ustekinumab)

Celltrion Collaborated with Rani Therapeutics for the Development of RT-111 (biosimilar, ustekinumab)

January 9, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us